- Home
- SACH vs ESLA Comparison
SACH vs ESLA Comparison
Compare SACH & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SACH | ESLA |
|---|---|---|
| Founded | 2010 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 32.0M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SACH | ESLA |
|---|---|---|
| Price | $0.99 | $0.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 160.4K | 32.4K |
| Earning Date | 05-06-2026 | 05-26-2026 |
| Dividend Yield | ★ 19.23% | N/A |
| EPS Growth | ★ 104.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $57,500,000.00 | N/A |
| Revenue This Year | $145.00 | N/A |
| Revenue Next Year | $6.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.76 | $0.59 |
| 52 Week High | $1.45 | $3.15 |
Technical Indicators
Market Signals| Indicator | SACH | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 66.41 | N/A |
| Support Level | $0.91 | N/A |
| Resistance Level | $0.98 | N/A |
| Average True Range (ATR) | 0.03 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 77.99 | 0.00 |
Price Performance
Historical ComparisonAbout SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.